Chlorinated tetralin compounds and pharmaceutical compositions

1. A method of treating a desmoid tumor in a patient in need thereof comprising orally administering to the patient a pharmaceutical composition comprising a compound of Formula IB

or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the compound of Formula IB or a pharmaceutically acceptable salt thereof in the pharmaceutical composition is present in an amount of about 1 μg to about 300 μg.

3. The method of claim 1 , wherein the compound of Formula IB or a pharmaceutically acceptable salt thereof in the pharmaceutical composition is present in an amount of about 1 μg to about 250 μg.

4. The method of claim 1 , wherein the compound of Formula IB or a pharmaceutically acceptable salt thereof in the pharmaceutical composition is present in an amount of about 1 μg to about 150 μg.

5. The method of claim 1 , wherein the compound of Formula IB or a pharmaceutically acceptable salt thereof in the pharmaceutical composition is present in an amount of about 1 μg to about 100 μg.

6. The method of claim 1 , wherein the compound of Formula IB or a pharmaceutically acceptable salt thereof in the pharmaceutical composition is present in an amount of about 1 μg to about 50 μg.

7. The method of claim 1 , wherein the pharmaceutical composition further comprises nirogacestat or a pharmaceutically acceptable salt thereof.

8. The method of claim 7 , wherein the compound of Formula IB or pharmaceutically acceptable salt thereof in the pharmaceutical composition is present in an amount of about 1 μg to about 300 μg.

9. The method of claim 8 , wherein the pharmaceutical composition comprises 50 mg nirogacestat or a pharmaceutically acceptable salt thereof.

10. The method of claim 7 , wherein the compound of Formula IB or pharmaceutically acceptable salt thereof in the pharmaceutical composition is present in an amount of about 1 μg to about 250 μg.

11. The method of claim 10 , wherein the pharmaceutical composition comprises 50 mg nirogacestat or a pharmaceutically acceptable salt thereof.

12. The method of claim 7 , wherein the compound of Formula IB or pharmaceutically acceptable salt thereof in the pharmaceutical composition is present in an amount of about 1 μg to about 150 μg.

13. The method of claim 12 , wherein the pharmaceutical composition comprises 50 mg nirogacestat or a pharmaceutically acceptable salt thereof.

14. The method of claim 7 , wherein the compounds of Formula IB or pharmaceutically acceptable salt thereof in the pharmaceutical composition is present in an amount of about 1 μg to about 100 μg.

15. The method of claim 14 , wherein the pharmaceutical composition comprises 50 mg nirogacestat or a pharmaceutically acceptable salt thereof.

16. The method of claim 7 , wherein the compound of Formula IB or pharmaceutically acceptable salt thereof in the pharmaceutical composition is present in an amount of about 1 μg to about 50 μg.

17. The method of claim 16 , wherein the pharmaceutical composition comprises 50 mg nirogacestat or a pharmaceutically acceptable salt thereof.